Liraglutide relieves myocardial damage by promoting autophagy via AMPK-mTOR signaling pathway in zucker diabetic fatty rat
Authors:
- 1 June 2017
- journal article
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 448, 98-107
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failureEndocrine, 2016
- The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanismJournal of Translational Medicine, 2016
- Reactive oxygen species are involved in insulin-dependent regulation of autophagy in primary rat podocytesThe International Journal of Biochemistry & Cell Biology, 2016
- AMPK activation by glucagon-like peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in adult cardiomyocytesAmerican Journal of Physiology-Heart and Circulatory Physiology, 2014
- LC3 and p62 as Diagnostic Markers of Drug-induced Autophagic Vacuolar CardiomyopathyAmerican Journal of Surgical Pathology, 2013
- Phosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing to MitophagyScience, 2011
- Glucagon-Like Peptide (GLP)-1(9-36)Amide-Mediated Cytoprotection Is Blocked by Exendin(9-39) Yet Does Not Require the Known GLP-1 ReceptorEndocrinology, 2010
- Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent PathwaysCirculation, 2008
- Glucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion InjuryDiabetes, 2005
- Hyperglycemia-Induced Apoptosis in Mouse MyocardiumDiabetes, 2002